The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19

Objectives. Vaccination against SARS-CoV-2 is essential to mitigate the personal, social and global impact of the coronavirus disease (COVID-19) as we move from a pandemic to an endemic phase. Vaccines are now required that offer broad, long-lasting immunological protection from infection in additio...

ver descrição completa

Detalhes bibliográficos
Autores: Borralleras, Cristina, Castrodeza Sanz, Javier, Cámara Hijón, Carmen, Eiros, José Mª, Fernández-Prada, María, Gil de Miguel, Ángel, Mirada Masip, Gloria, Moraga-Llop, Fernando, Ocaña Rodríguez, Daniel, Puig-Barberà, Joan, Vázquez, Jorge, Serra Gironella, Joan, de Cambra, Salomé
Formato: artículo
Fecha de publicación:2023
País:España
Recursos:Institut de Recerca i Tecnologia Agroalimentàries (IRTA)
Repositorio:IRTA Pubpro. Open Digital Archive
OAI Identifier:oai:repositori.irta.cat:20.500.12327/2768
Acesso em linha:http://hdl.handle.net/20.500.12327/2768
http://www.doi.org/10.37201/req/046.2023
Access Level:acceso abierto
Palavra-chave:619
id ES_032326081ffcf244ea3ee0affc7b82ca
oai_identifier_str oai:repositori.irta.cat:20.500.12327/2768
network_acronym_str ES
network_name_str España
repository_id_str
spelling The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19Borralleras, CristinaCastrodeza Sanz, JavierCámara Hijón, CarmenEiros, José MªFernández-Prada, MaríaGil de Miguel, ÁngelMirada Masip, GloriaMoraga-Llop, FernandoOcaña Rodríguez, DanielPuig-Barberà, JoanVázquez, JorgeSerra Gironella, Joande Cambra, Salomé619Objectives. Vaccination against SARS-CoV-2 is essential to mitigate the personal, social and global impact of the coronavirus disease (COVID-19) as we move from a pandemic to an endemic phase. Vaccines are now required that offer broad, long-lasting immunological protection from infection in addition to protection from severe illness and hospitalisation. Here we present a review of the evidence base for a new COVID-19 vaccine, PHH-1V (Bimervax®; HIPRA HUMAN HEALTH S.L.U), and the results of an expert consensus. Materials and methods. The expert committee consisted of Spanish experts in medicine, family medicine, paediatrics, immunology, microbiology, nursing, and veterinary medicine. Consensus was achieved using a 4-phase process consisting of a face-to-face meeting during which the scientific evidence base was reviewed, an online questionnaire to elicit opinions on the value of PHH-1V, a second face-to-face update meeting to discuss the evolution of the epidemiological situation, vaccine programmes and the scientific evidence for PHH-1V and a final face-to-face meeting at which consensus was achieved. Results. The experts agreed that PHH-1V constitutes a valuable novel vaccine for the development of vaccination programmes aimed towards protecting the population from SARS-CoV-2 infection and disease. Consensus was based on evidence of broad-spectrum efficacy against established and emerging SARS-CoV-2 variants, a potent immunological response, and a good safety profile. The physicochemical properties of the PHH-1V formulation facilitate handling and storage appropriate for global uptake. Conclusions- The physicochemical properties, formulation, immunogenicity and low reactogenic profile of PHH-1V confirm the appropriateness of this new COVID-19 vaccine.info:eu-repo/semantics/publishedVersionSociedad Española de QuimioterapiaProducció AnimalSanitat Animal202420242023info:eu-repo/semantics/article9application/pdfhttp://hdl.handle.net/20.500.12327/2768http://www.doi.org/10.37201/req/046.2023reponame:IRTA Pubpro. Open Digital Archiveinstname:Institut de Recerca i Tecnologia Agroalimentàries (IRTA)InglésRevista Española de QuimioterapiaAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:repositori.irta.cat:20.500.12327/27682026-06-16T08:51:17Z
dc.title.none.fl_str_mv The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19
title The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19
spellingShingle The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19
Borralleras, Cristina
619
title_short The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19
title_full The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19
title_fullStr The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19
title_full_unstemmed The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19
title_sort The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19
dc.creator.none.fl_str_mv Borralleras, Cristina
Castrodeza Sanz, Javier
Cámara Hijón, Carmen
Eiros, José Mª
Fernández-Prada, María
Gil de Miguel, Ángel
Mirada Masip, Gloria
Moraga-Llop, Fernando
Ocaña Rodríguez, Daniel
Puig-Barberà, Joan
Vázquez, Jorge
Serra Gironella, Joan
de Cambra, Salomé
author Borralleras, Cristina
author_facet Borralleras, Cristina
Castrodeza Sanz, Javier
Cámara Hijón, Carmen
Eiros, José Mª
Fernández-Prada, María
Gil de Miguel, Ángel
Mirada Masip, Gloria
Moraga-Llop, Fernando
Ocaña Rodríguez, Daniel
Puig-Barberà, Joan
Vázquez, Jorge
Serra Gironella, Joan
de Cambra, Salomé
author_role author
author2 Castrodeza Sanz, Javier
Cámara Hijón, Carmen
Eiros, José Mª
Fernández-Prada, María
Gil de Miguel, Ángel
Mirada Masip, Gloria
Moraga-Llop, Fernando
Ocaña Rodríguez, Daniel
Puig-Barberà, Joan
Vázquez, Jorge
Serra Gironella, Joan
de Cambra, Salomé
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Producció Animal
Sanitat Animal
dc.subject.none.fl_str_mv 619
topic 619
description Objectives. Vaccination against SARS-CoV-2 is essential to mitigate the personal, social and global impact of the coronavirus disease (COVID-19) as we move from a pandemic to an endemic phase. Vaccines are now required that offer broad, long-lasting immunological protection from infection in addition to protection from severe illness and hospitalisation. Here we present a review of the evidence base for a new COVID-19 vaccine, PHH-1V (Bimervax®; HIPRA HUMAN HEALTH S.L.U), and the results of an expert consensus. Materials and methods. The expert committee consisted of Spanish experts in medicine, family medicine, paediatrics, immunology, microbiology, nursing, and veterinary medicine. Consensus was achieved using a 4-phase process consisting of a face-to-face meeting during which the scientific evidence base was reviewed, an online questionnaire to elicit opinions on the value of PHH-1V, a second face-to-face update meeting to discuss the evolution of the epidemiological situation, vaccine programmes and the scientific evidence for PHH-1V and a final face-to-face meeting at which consensus was achieved. Results. The experts agreed that PHH-1V constitutes a valuable novel vaccine for the development of vaccination programmes aimed towards protecting the population from SARS-CoV-2 infection and disease. Consensus was based on evidence of broad-spectrum efficacy against established and emerging SARS-CoV-2 variants, a potent immunological response, and a good safety profile. The physicochemical properties of the PHH-1V formulation facilitate handling and storage appropriate for global uptake. Conclusions- The physicochemical properties, formulation, immunogenicity and low reactogenic profile of PHH-1V confirm the appropriateness of this new COVID-19 vaccine.
publishDate 2023
dc.date.none.fl_str_mv 2023
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12327/2768
http://www.doi.org/10.37201/req/046.2023
url http://hdl.handle.net/20.500.12327/2768
http://www.doi.org/10.37201/req/046.2023
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Revista Española de Quimioterapia
dc.rights.none.fl_str_mv Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 9
application/pdf
dc.publisher.none.fl_str_mv Sociedad Española de Quimioterapia
publisher.none.fl_str_mv Sociedad Española de Quimioterapia
dc.source.none.fl_str_mv reponame:IRTA Pubpro. Open Digital Archive
instname:Institut de Recerca i Tecnologia Agroalimentàries (IRTA)
instname_str Institut de Recerca i Tecnologia Agroalimentàries (IRTA)
reponame_str IRTA Pubpro. Open Digital Archive
collection IRTA Pubpro. Open Digital Archive
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402704908910592
score 15,300719

Registos relacionados